Use of biologics for psoriasis in Central and Eastern European countries.

Use of biologics for psoriasis in Central and Eastern European countries.

Item
http://www.wikidata.org/entity/Q38586836
Determinants of biological drug survival in rheumatoid arthritis: evidence from a Hungarian rheumatology center over 8 years of retrospective data.Key drivers for market penetration of biosimilars in Europe.Characteristics and risk profile of psoriasis patients included in the Czech national registry BIOREP and a comparison with other registries.Broader concepts of quality of life measurement, encompassing validation.Supply-side and demand-side policies for biosimilars: an overview in 10 European member states.A detailed analysis of 'not relevant' responses on the DLQI in psoriasis: potential biases in treatment decisions.Discrepancies between the Dermatology Life Quality Index and utility scores.Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients.Is the DLQI appropriate for medical decision-making in psoriasis patients?Pros and cons of biological therapy in psoriasis.
P2860

Use of biologics for psoriasis in Central and Eastern European countries.

Item
http://www.wikidata.org/entity/Q38586836
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Use of biologics for psoriasis in Central and Eastern European countries.
@en
type
label
Use of biologics for psoriasis in Central and Eastern European countries.
@en
prefLabel
Use of biologics for psoriasis in Central and Eastern European countries.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P5875
P698
P356
P1433
P1476
Use of biologics for psoriasis in Central and Eastern European countries.
@en
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P5875
P698